Hiraiwa, Hiroaki http://orcid.org/0000-0002-1606-7037
Okumura, Takahiro http://orcid.org/0000-0001-5076-2052
Murohara, Toyoaki http://orcid.org/0000-0003-2723-6243
Funding for this research was provided by:
Nagoya University
Article History
Accepted: 12 March 2024
First Online: 4 April 2024
Declarations
:
: Open Access funding provided by Nagoya University. The authors have no relevant financial or non-financial interests to disclose. The authors did not receive support from any organization for the submitted work.
: Considering that this is a review article, no research was conducted, and it did not involve any subjects, rendering ethical approval unnecessary.
: Hiroaki Hiraiwa received lecture fees from Kowa Co. Ltd., Bayer Pharmaceutical Co. Ltd., and Daiichi-Sankyo Co. Ltd. Takahiro Okumura received research grants from Ono Pharmaceutical Co. Ltd., Bayer Pharmaceutical Co. Ltd., Daiichi-Sankyo Co. Ltd., Amgen Astellas BioPharma K.K., Pfizer Japan Inc., Alnylam Pharmaceuticals, Inc., and Alexion Pharmaceuticals, Inc. Takahiro Okumura received lecture fees from Ono Pharmaceutical Co. Ltd., Otsuka Pharma Ltd., Novartis Pharma K.K., and AstraZeneca K.K. Toyoaki Murohara received an unrestricted research grant from the Department of Cardiology, Nagoya University Graduate School of Medicine, from Astellas Pharma Inc., Daiichi-Sankyo Co. Ltd., Dainippon Sumitomo Pharma Co. Ltd., Kowa Co. Ltd., MSD K.K., Mitsubishi Tanabe Pharma Co., Nippon Boehringer Ingelheim Co. Ltd., Novartis Pharma K.K., Otsuka Pharma Ltd., Pfizer Japan Inc., Sanofi-Aventis K.K., Takeda Pharmaceutical Co. Ltd., and Teijin Pharma Ltd.
: Not applicable.
: Not applicable.
: HH contributed to the conceptualization, investigation, and visualization of this review. TO and TM contributed to the investigation and visualization. All authors contributed to writing and reviewing the article. All authors have read and approved the final version of the manuscript.
: Not applicable.
: Not applicable.
: Not applicable.